Better Outcomes Rely On Better Biomarkers
With some therapeutics proving ineffective in as many as 75% of the patients they are expected to help, the need for personalized and precision medicine is clear. Because the use of selection biomarkers can triple drug development success rates, we have expanded our portfolio to test more than routine safety and efficacy parameters.
As your global partner for integrated clinical trial laboratory and diagnostic solutions, our goal at Cerba Research is to generate early scientific insights that optimize your protocol. Our large portfolio of next-generation assays are designed for targeted approaches or broad immune profiling with multifactorial biomarkers. Benefit from our customized service to obtain innovative, flexible, and tailored solutions grounded in expert science.
Optimize Biomarker Strategies For Precision Medicine
Beyond monitoring the efficacy of a drug by PK & PD, biomarkers are increasing in importance and evolving quickly to:
- Guide dose selection
- Characterize mode of action
- Stratify patients
- Predict drug response
- Aid in prognosis
- Monitor disease & drug resistance
Streamline your development and ensure quality
Our quality-driven approach includes analytically validated assays and GLP and/or CLIA-certified labs.
We tailor the best possible solution that meets your requirements to:
- Transfer assays developed in-house
- Assess method feasibility
- Develop and validate customized assays
- Obtain detailed sample analyses
Biomarker insights with Cerba Research
Biomarkers can triple drug development success rates when used in clinical research. While scientific and technological advances have led to the discovery of more circulating biomarker candidates, the challenge lies in validating those biomarkers. Cerba Research takes a personalized approach to biomarker assay development and validation to help clients improve their odds of success. This approach involves the experience of our leading scientists and our five-continent laboratory network.
Our highly specialized custom assays, innovative anatomical pathology biomarker support and biomarker strategies de-risk study conduct and generate the data you need to bring new therapies to light.
From translational research to clinical through commercialization, Cerba Research actuates real-world data to help you reach patients and bring clarity to complex research.
Gain insights to help solve development challenges with our state of the art platforms circulating biomarkers tested
Benefits of state of the art platform including:
- MSD S600 Meso Scale Discovery
- ELISA platform
- Luminex Magpix
- Quanterix Simoa HD1
- Ella ProteinSimple system
- LC-MS/MS
- Immunohistochemistry platforms
Circulating biomarkers
Here are most of the circulating biomarkers we currently test for. Because new tests are added frequently, please reach out for our complete list.
Discover how Cerba Research ensure the patients monitoring
Reach out to our experts and discover how we can help you advance your research
Contact Us